October 2024 - Portal presented the poster "Addressing the Challenges of Highly Viscous Formulations Using a Needle-Free Technology" at the The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona.
October 2024 - Portal recently shared its latest research at The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona. The poster "Addressing the Challenges of Highly Viscous Formulations
Using a Needle-Free Technology" showed ex-vivo testing results which demonstrated PRIME Needle-Free injector can eject consistently and faster than a needle and syringe, while depositing the injectate at a similar depth in the subcutaneous space.
The ability for PRIME NF to eject high viscosity fluids consistently and rapidly could open the doors for new therapies as well as increase patient access to a more agreeable method of drug delivery. Having a needle-free system not only quells the common fear of needles but also boasts faster and more reliable injection times than a mechanical autoinjector. The findings of this study hint at the prospect of pushing beyond the constraints imposed by current needle-based injection devices.
October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
December 2019 - Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
November 21, 2023 - Patrick Anquetil, CEO of Portal Instruments, takes the stage at LSI's 2023 Emerging MedTech Summit in Dana Point, California. Tune in to the recorded session to hear Dr. Anquetil dive into the innovative world of of needle-free and Portal's groundbreaking needle-free technology.
Please fill out the details below and we will get back to you shortly.